TXMD
TherapeuticsMD, Inc.$2.17+0.35 (+19.51%)Prev Close$1.82·MCap$26.6M·P/E—·Vol242.1K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$0.00
●
Active Insiders
0
last 12 mo
TXMD Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 14, 2025 | Thompson Tommy G | Director | Buy | 325 | $1.00 | $325.58 | 0 |
| Apr 10, 2025 | Walker Marlan D | Chief Executive Officer | Buy | 2,303 | $0.87 | $2.0K | 73,149 |
| Aug 26, 2024 | Collins Cooper C. | Buy | 4,094 | $1.73 | $7.1K | 52,016 | |
| Aug 23, 2024 | Collins Cooper C. | Buy | 1,200 | $1.70 | $2.0K | 47,922 | |
| Dec 7, 2023 | Walker Marlan D | Chief Executive Officer | Sell | 19,050 | $2.29 | $43.7K | 67,115 |
| Apr 14, 2023 | Walker Marlan D | Chief Executive Officer | Sell | 1,170 | $3.65 | $4.3K | 12,307 |
| Jan 30, 2023 | Donegan Michael C | Prin. Fin. and Acctg. Officer | Sell | 1,697 | $5.08 | $8.6K | 11,902 |
| Jan 25, 2023 | Donegan Michael C | Prin. Fin. and Acctg. Officer | Sell | 1,309 | $5.34 | $7.0K | 7,617 |
| Dec 12, 2022 | Rubric Capital Management LP | 10% Owner | Buy | 14,825 | $6.09 | $90.3K | 1,757,191 |
| Dec 9, 2022 | Bernick Brian | Co-Chief Executive Officer | Sell | 1,255 | $5.28 | $6.6K | 4,192 |
| Dec 9, 2022 | Donegan Michael C | Interim CFO/CAO/VP of Finance | Sell | 910 | $4.78 | $4.3K | 4,554 |
| Dec 9, 2022 | Glickman Mark A | Co-Chief Executive Officer | Sell | 440 | $4.92 | $2.2K | 1,294-25% |
| Dec 9, 2022 | Rubric Capital Management LP | 10% Owner | Buy | 20,413 | $5.66 | $115.6K | 1,742,366 |
| Dec 9, 2022 | Walker Marlan D | General Counsel | Sell | 1,048 | $4.95 | $5.2K | 6,685 |
| Dec 8, 2022 | Naughton Gail K | Director | Sell | 3,922 | $5.26 | $20.6K | 0Exit |
| Aug 1, 2022 | Rubric Capital Management LP | 10% Owner | Buy | 565,000 | $4.72 | $2.67M4.9% OS | 1,721,953+49% |
| Jul 19, 2022 | Rubric Capital Management LP | 10% Owner | Buy | 82,580 | $5.66 | $467.5K0.7% OS | 1,156,953 |
| Dec 2, 2021 | Donegan Michael C | CAO and VP of Finance | Sell | 29,790 | $0.54 | $15.9K | 99,368 |
| Nov 22, 2021 | Collins Cooper C. | Director | Buy | 1,000,000 | $0.58 | $578.5K8.6% OS | 2,236,864+81% |
| Aug 19, 2021 | Collins Cooper C. | Director | Buy | 1,000,000 | $0.73 | $725.0K8.6% OS | 1,236,864+422% |
| Aug 19, 2021 | Ling Karen | Director | Buy | 33,445 | $0.75 | $25.1K | 130,309+35% |
| Aug 18, 2021 | BISARO PAUL | Director | Buy | 50,000 | $0.79 | $39.5K | 196,864+34% |
| Aug 17, 2021 | Thompson Tommy G | Director | Buy | 11,000 | $0.87 | $9.6K | 715,600 |
| Aug 12, 2021 | DArecca James | Chief Financial Officer | Sell | 93,337 | $0.87 | $81.2K0.8% OS | 123,830-43% |
| May 18, 2021 | Thompson Tommy G | Director | Buy | 5,000 | $1.06 | $5.3K | 704,600 |
| May 12, 2021 | BORKOWSKI EDWARD | EVP, Operations | Sell | 44,252 | $1.04 | $46.0K | 59,248-43% |
| May 12, 2021 | Donegan Michael C | CAO and VP Finance | Sell | 4,842 | $1.04 | $5.0K | 14,158-25% |
| May 12, 2021 | Finizio Robert G | CEO | Sell | 67,697 | $1.04 | $70.4K0.6% OS | 17,991,636 |
| May 12, 2021 | Milligan John C.K. IV | Secretary/CEO of subsidiary | Sell | 44,252 | $1.04 | $46.0K | 1,752,703 |
| May 12, 2021 | Walker Marlan D | General Counsel | Sell | 21,592 | $1.04 | $22.5K | 28,908-43% |
TXMD Insider Buying Activity
The following table shows recent insider purchases of TherapeuticsMD, Inc. (TXMD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 14, 2025 | Thompson Tommy G | Director | Buy | 325 | $1.00 | $325.58 | 0 |
| Apr 10, 2025 | Walker Marlan D | Chief Executive Officer | Buy | 2,303 | $0.87 | $2.0K | 73,149 |
| Aug 26, 2024 | Collins Cooper C. | Buy | 4,094 | $1.73 | $7.1K | 52,016 | |
| Aug 23, 2024 | Collins Cooper C. | Buy | 1,200 | $1.70 | $2.0K | 47,922 | |
| Dec 12, 2022 | Rubric Capital Management LP | 10% Owner | Buy | 14,825 | $6.09 | $90.3K | 1,757,191 |
| Dec 9, 2022 | Rubric Capital Management LP | 10% Owner | Buy | 20,413 | $5.66 | $115.6K | 1,742,366 |
| Aug 1, 2022 | Rubric Capital Management LP | 10% Owner | Buy | 565,000 | $4.72 | $2.67M4.9% OS | 1,721,953+49% |
| Jul 19, 2022 | Rubric Capital Management LP | 10% Owner | Buy | 82,580 | $5.66 | $467.5K0.7% OS | 1,156,953 |
| Nov 22, 2021 | Collins Cooper C. | Director | Buy | 1,000,000 | $0.58 | $578.5K8.6% OS | 2,236,864+81% |
| Aug 19, 2021 | Collins Cooper C. | Director | Buy | 1,000,000 | $0.73 | $725.0K8.6% OS | 1,236,864+422% |
| Aug 19, 2021 | Ling Karen | Director | Buy | 33,445 | $0.75 | $25.1K | 130,309+35% |
| Aug 18, 2021 | BISARO PAUL | Director | Buy | 50,000 | $0.79 | $39.5K | 196,864+34% |
| Aug 17, 2021 | Thompson Tommy G | Director | Buy | 11,000 | $0.87 | $9.6K | 715,600 |
| May 18, 2021 | Thompson Tommy G | Director | Buy | 5,000 | $1.06 | $5.3K | 704,600 |
TXMD Insider Selling Activity
The following table shows recent insider sales of TherapeuticsMD, Inc. (TXMD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 7, 2023 | Walker Marlan D | Chief Executive Officer | Sell | 19,050 | $2.29 | $43.7K | 67,115 |
| Apr 14, 2023 | Walker Marlan D | Chief Executive Officer | Sell | 1,170 | $3.65 | $4.3K | 12,307 |
| Jan 30, 2023 | Donegan Michael C | Prin. Fin. and Acctg. Officer | Sell | 1,697 | $5.08 | $8.6K | 11,902 |
| Jan 25, 2023 | Donegan Michael C | Prin. Fin. and Acctg. Officer | Sell | 1,309 | $5.34 | $7.0K | 7,617 |
| Dec 9, 2022 | Bernick Brian | Co-Chief Executive Officer | Sell | 1,255 | $5.28 | $6.6K | 4,192 |
| Dec 9, 2022 | Donegan Michael C | Interim CFO/CAO/VP of Finance | Sell | 910 | $4.78 | $4.3K | 4,554 |
| Dec 9, 2022 | Glickman Mark A | Co-Chief Executive Officer | Sell | 440 | $4.92 | $2.2K | 1,294-25% |
| Dec 9, 2022 | Walker Marlan D | General Counsel | Sell | 1,048 | $4.95 | $5.2K | 6,685 |
| Dec 8, 2022 | Naughton Gail K | Director | Sell | 3,922 | $5.26 | $20.6K | 0Exit |
| Dec 2, 2021 | Donegan Michael C | CAO and VP of Finance | Sell | 29,790 | $0.54 | $15.9K | 99,368 |
| Aug 12, 2021 | DArecca James | Chief Financial Officer | Sell | 93,337 | $0.87 | $81.2K0.8% OS | 123,830-43% |
| May 12, 2021 | BORKOWSKI EDWARD | EVP, Operations | Sell | 44,252 | $1.04 | $46.0K | 59,248-43% |
| May 12, 2021 | Donegan Michael C | CAO and VP Finance | Sell | 4,842 | $1.04 | $5.0K | 14,158-25% |
| May 12, 2021 | Finizio Robert G | CEO | Sell | 67,697 | $1.04 | $70.4K0.6% OS | 17,991,636 |
| May 12, 2021 | Milligan John C.K. IV | Secretary/CEO of subsidiary | Sell | 44,252 | $1.04 | $46.0K | 1,752,703 |
| May 12, 2021 | Walker Marlan D | General Counsel | Sell | 21,592 | $1.04 | $22.5K | 28,908-43% |
TXMD Insiders
Similar Stocks to TXMD
VTRS
Viatris Inc.
$16.41+0.71%
$18.55B
ELAN
Elanco Animal Health Incorporated
$24.26+0.87%
$11.83B
AMRX
Amneal Pharmaceuticals, Inc.
$16.39+0.34%
$5.21B
INDV
Indivior Pharmaceuticals Inc
$38.27+0.35%
$4.76B
SUPN
Supernus Pharmaceuticals, Inc.
$44.56-2.17%
$2.64B
ANIP
ANI Pharmaceuticals, Inc.
$81.54-0.13%
$1.86B
HROW
Harrow Health, Inc.
$37.67+0.05%
$1.29B
PAHC
Phibro Animal Health Corporation
$32.05+2.51%
$1.16B